Jounce Therapeutics, Inc. (JNCE) financial statements (2021 and earlier)

Company profile

Business Address 780 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments169176152164190212233
Cash and cash equivalents53663840485350
Short-term investments116109114124142158183
Receivables    000
Prepaid expense    222
Other undisclosed current assets5556   
Total current assets:174181157170192214235
Noncurrent Assets
Operating lease, right-of-use asset181819 
Property, plant and equipment11121213141415
Long-term investments and receivables29 963 
Long-term investments29 963 
Restricted cash and investments   1   
Other noncurrent assets2222333
Other undisclosed noncurrent assets   18   
Total noncurrent assets:32413343222018
TOTAL ASSETS:206222191213214234253
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11101010101110
Accounts payable2334333
Accrued liabilities9776787
Deferred revenue  65 
Debt333    
Deferred rent credit    000
Contract with customer, liability63555956
Other liabilities0000000
Other undisclosed current liabilities   3   
Total current liabilities:14137876667066
Noncurrent Liabilities
Long-term debt and lease obligation171818    
Operating lease, liability171818 
Liabilities, other than long-term debt  524456179
Deferred revenue  5 
Contract with customer, liability24435977
Deferred rent credit    222
Other liabilities     00
Other undisclosed noncurrent liabilities   19   
Total noncurrent liabilities:17182343456179
Total liabilities:3131101119110131145
Stockholders' equity
Stockholders' equity attributable to parent1751919094104103108
Common stock0000000
Additional paid in capital282276273271268265263
Accumulated other comprehensive income (loss)0000(0)(0)(0)
Accumulated deficit(107)(84)(183)(176)(164)(162)(154)
Total stockholders' equity:1751919094104103108
TOTAL LIABILITIES AND EQUITY:206222191213214234253

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit: 1191711201519
Operating expenses(24)(22)(25)(24)(23)(23)(25)
Operating income (loss):(24)98(8)(13)(3)(9)(6)
Nonoperating income
(Other Nonoperating income)
1111111
Income (loss) from continuing operations before income taxes:(23)99(7)(12)(2)(8)(5)
Income tax expense(0)(0)(0)(0)   
Other undisclosed loss from continuing operations    (0)  
Net income (loss) available to common stockholders, diluted:(23)99(7)(12)(2)(8)(5)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(23)99(7)(12)(2)(8)(5)
Comprehensive income (loss):(23)99(7)(12)(2)(8)(5)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)00000
Comprehensive income (loss), net of tax, attributable to parent:(23)99(7)(12)(2)(8)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: